Piramal Pharma Limited
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Piramal Pharma Limited's past years’ income statements indicate that its last revenue has increased compared to the previous period by 164% to $81,711,600,000. Profit margin reached 0%. Total operating expenses were $48,476,500,000.

Profit Margin

Piramal Pharma Limited (NSE:PPLPHARMA.NS): Profit margin
2021 29.38B 5.71B 19.45%
2022 30.95B 3.75B 12.15%
2024 81.71B 178.2M 0.22%

PPLPHARMA.NS Income Statement (2020 – 2023)

2023 2021 2020
Revenue
Revenue
81.71B30.95B29.38B
Cost of revenue
32.61B15.49B12.78B
Gross profit
49.09B15.46B16.60B
Operating exp.
Research and development
1.00B619.4M691.4M
Selling and marketing
3.04B1.75B1.27B
Total operating expenses
48.47B12.78B11.79B
Operating income
4.31B5.60B5.50B
Other income (expenses), net
-2.52B-752.2M1.36B
Income before tax
1.79B4.24B6.86B
Income tax expense
1.61B811.8M1.15B
Net income
178.2M3.75B5.71B
Earnings per share
Basic EPS
0.143.114.68
Diluted EPS
0.143.114.68
Data sourceData sourceData source